Member Info for Laura2022

This was a really good summary from KingH that was lost in the IT outage debacle

DosemeRX has 100,000 of user license sold....across 29 Countries World Wide

The Software license is $2400 each.....

PYC's potential moving forward with Dosemerx is exponential

The Physiomics software will be made available to selected DoseMe clients, initially on a research basis, but with the objective of adding paid functionality later, in particular relating to the potential for the software to be able to provide decision support around the use of granulocyte colony stimulating factor (“GCSF”).

lets not forget and im sure Long term shareholders will appreciate this has been in development through years of grants and trials....hopefully the rewards will be significant.....

Frankly this MC is ridiculously undervalued and can / should be multiples and multiples

Lovely to see some nice buying today

What a finish

In my view a company called PYC could do the same x 10 rise as

400k buy shown as a sell

And what about your total lies about a placing?

Totally agree Newuncle

He's shameless and stupid

He lies on every stock he's in (or not in)

You really are the worst ..this is your despicable nonsense from just 2 days ago

Reported to FCA

Ilovesushi

Posted in: CPX

Posts: 4,230

Price: 0.3375

No Opinion

RE: Possible Placing to come23 Jul 2024 20:37

Profit is still in the distance. They will not have enough cash to take it to that point. Its not if a placing will take place but when?

Who says forward selling does not take place? The shares were suspended for that that reason when they announced the last placing.

Looks like forward selling is taking place atm. Lots of buys so shares are coming from somewhere. To me this looks like forward selling of shares not yet issued. Or the selling of borrowed shares. Same thing.

Placing is coming.

If i had been here for 2yrs+ I would at least add more to either tale a stand against CEO or lower average if it does go private

Or a fund could buy a large chunk between now and GM

Someone could get this asset and de rail CEO plans

You should get a shareholder group and stop him ?

Perhaps reading the small print would help

Further to the announcement on 19 March 2024, Suzanne Dilly will remain with the Company for a one-month handover period to ensure business continuity and will step down from the ValiRx Group after that period

I wonder what 4% holder China Non Ferrous will do given the mine is practically on their door step

Great to see

On other matters very risky CGH might be worth a small wager on a bid coming in before August 16th

Martin Gouldstone, Chairman of ValiRx commented "I am delighted to Chair ValiRx at this pivotal time in the business's journey, and am excited to work with Mark as the new proposed CEO and Cathy as an Executive Director to help us to realise our potential."

Physiomics signs further project agreement with CellCentric

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a further contract by existing UK based biotech client, CellCentric. The value of the contract is not disclosed but is expected to complete in the first half of 2020.

The project will involve pharmacokinetic and pharmacodynamic modelling and build on the work completed over the course of 2019 in support of the clinical development of CellCentric’s lead asset CCS1477.

Total round over $60m, as previous $25 million loan note from Pfizer converts to equity; Irena Melnikova, Partner at Pfizer Ventures also joins the Board

Cambridge, UK, July 24th, 2024 – CellCentric, a clinical stage biotechnology company, today announces that it has secured a $35 million investment from RA Capital Management. The funding will support the continued development of CellCentric’s oral drug inobrodib, a first-in-class p300/CBP inhibitor, to treat multiple myeloma.

That's good as CellCentric a key client of PYC

Announced